biote Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.3%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$190.6Mnext fiscal year
FY EPS (est.)
$0.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly44.9MTarget: above $190 million for FY 2026
Adjusted EBITDA Quarterly8.7MTarget: above $38 million for FY 2026
Procedure Revenue Quarterly31.3MTarget: Return to growth in H2 2026
Dietary Supplement Revenue Quarterly11MTarget: Mid-to-high single-digit growth for FY 2026
Watch Items
- Asteria Health Pellet Recall RecoveryTrigger: Resolution of supply constraints and inventory restorationAction: Monitor gross profit margin recovery (which fell to 68.9% in Q1 2026 due to recall costs) and procedure volume stabilization.
- Sales Force Expansion and ProductivityTrigger: Ramp-up of 25+ newly hired sales personnel (totaling 120)Action: Track clinic productivity and the conversion of newly trained practitioners into active procedure kit orders.
- Executive Leadership TransitionTrigger: Appointment of Robert Peterson as Interim CEO and Marc Beer as Executive ChairmanAction: Evaluate execution of the commercial framework and strategic priorities under the new leadership structure.
Research as of 19 Jun 2026